Review



cells  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    MedChemExpress cells
    Cells, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 25 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vbit+4/VBIT-4/pm42962830-120-3-13
    Average 94 stars, based on 25 article reviews
    cells - by Bioz Stars, 2026-11
    94/100 stars

    Images

    Related Articles

    other:

    Article Title: Chronic sensing of host-derived lipids is an all-in-one signal that primes and activates NLRP3
    Article Snippet: Bone marrow cells were differentiated into macrophages at 37 °C, 5% CO 2 for 6-7 days in DMEM (Thermo Fisher Scientific, Cat# 11965092) containing 30% L-929 conditioned media and supplemented with 10 % heat-inactivated FBS (Thermo Fisher Scientific, Cat# A5256701), 2 mM L-glutamine (Thermo Fisher Scientific, Cat# 25030081) and 100 μg/ml penicillin/streptomycin (Thermo Fisher Scientific, Cat# 15140122).

    Article Title: CypD Dependent mPTP Opening Is Crucial for Oxidized Mitochondrial DNA Release in Ferroptosis
    Article Snippet: RSL3 (T3646), erastin (T1765), ML210 (T8375), FINO2 ( T60084 ), CsA (T0945), DFO (T124358), BSO (T5471), TH5487 (T8119), SU0268 (T9119), Fer‐1 (T6500), VBIT‐4 ( T13287 ), H‐151 (T5674) and RU.521 (T5486) were ordered from TargetMol; Arachidonic acid (HY‐109590), Ardenic acid (HY‐W013215), and NIM811 (HY‐P0025) was purchased from MedChemExpress; IKE (MC2024) was purchased from MeilunBio.

    Article Title: Ca 2+ and DRP1 drive endocytic lysosome reformation at tripartite contact sites
    Article Snippet: The following reagents were used in this study: YM-201636 (Cat. HY-13228/ MCE), Bafilomycin (Cat. BML-CM110-0100/ enzo live sciences), Halt phosphatase inhibitor (Cat. 78420/ Thermo Fisher Scientific), Biotin (Cat. B450/ Sigma), Cycloheximide (Cat. C1988-1G/ Sigma), LysotrackerTM Deep Red (Cat. L12492/ ThermoFisher), Magic Red Cathepsin B Kit (Cat. ICT938/ Bio-Rad), MitoTracker Deep Red FM (Cat. M22426/ ThermoFisher), Filipin complex ready-made solution (Cat. SAE0088/ Sigma), CellMask Green Actin Tracking Stain (Cat. A57243/ ThermoFisher), Hoechst 33342 Fluorescent Nucleic Acid Stain (Cat# 639/ ImmunoChemistry technologies).

    Article Title: CypD Dependent mPTP Opening Is Crucial for Oxidized Mitochondrial DNA Release in Ferroptosis.
    Article Snippet: RSL3 (T3646), erastin (T1765), ML210 (T8375), FINO2 (T60084), CsA (T0945), DFO (T124358), BSO (T5471), TH5487 (T8119), SU0268 (T9119), Fer-1 (T6500), VBIT-4 (T13287), H-151 (T5674) and RU.521 (T5486) were ordered from TargetMol; Arachidonic acid (HY-109590), Ardenic acid (HY-W013215), and NIM811 (HYP0025) was purchased from MedChemExpress; IKE (MC2024) was purchased from MeilunBio.

    Cell Culture:

    Article Title: From disease model to therapeutic insight: An engineered hydrogel reveals the role of matrix viscous dissipation in intervertebral disc degeneration
    Article Snippet: .. Inhibitors in cell culture were used at the following concertation: 0.25 μM VP to inhibit YAP (MCE, China, CL 318952), 10 μM PF-573228 (MCE, China, HY-10461) to inhibit p-FAK, 1 μg ml −1 ITGB 1-blocking antibody (Abcam, NBP2-16974), VBIT-4 (MCE, China, HY-129122) to inhibit mitochondria damage and SN-011 (MCE, China, HY-145010) to inhibit STING. .. Agonists in cell culture were used at the following concertation: 1.5 μM PY-60 to activate YAP (MCE, China, HY-141644), 0.8 μM Pyrintegrin to activate ITGB1 (MCE, China, HY-13306) and 10 nM ZINC40099027 to activate FAK (MCE, China, HY-134570).

    Inhibition:

    Article Title: Mitochondrial DNA-driven senescence-associated secretory phenotype promotes the development of bronchopulmonary dysplasia.
    Article Snippet: Bronchopulmonary dysplasia (BPD) is characterized by arrested alveolar development and disrupted vascular growth in preterm infants.. Although cellular senescence has been well established in age-related diseases, such as chronic lung diseases, its role in developmental lung diseases originating in the neonatal period remains largely unknown.. Here, we investigated the role and underlying mechanisms of the senescence-associated secretory phenotype (SASP) in BPD using targeted inhibitor treatments and rescue strategies.



    Similar Products

    95
    TargetMol vbit
    Vbit, supplied by TargetMol, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vbit+4/VBIT-4/pm42962946-55-9-14
    Average 95 stars, based on 1 article reviews
    vbit - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    94
    MedChemExpress cells
    Cells, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vbit+4/VBIT-4/pm42962830-120-3-13
    Average 94 stars, based on 1 article reviews
    cells - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    99
    MedChemExpress vbit 4 medchemexpress llc hy 129122 mdivi 1 medchemexpress llc hy 15886 group
    Vbit 4 Medchemexpress Llc Hy 129122 Mdivi 1 Medchemexpress Llc Hy 15886 Group, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vbit+4/Mdivi-1/pm42962830-195-0-1
    Average 99 stars, based on 1 article reviews
    vbit 4 medchemexpress llc hy 129122 mdivi 1 medchemexpress llc hy 15886 group - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    94
    MedChemExpress vbit-4
    Vbit 4, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vbit+4/VBIT-4/custom%40hy-129122%4042410595
    Average 94 stars, based on 1 article reviews
    vbit-4 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress vbit 4
    Vbit 4, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vbit+4/VBIT-4/pmc12926610-344-38-39
    Average 94 stars, based on 1 article reviews
    vbit 4 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    95
    TargetMol voltage dependent anion channel 1 oligomerization inhibitor 4
    Voltage Dependent Anion Channel 1 Oligomerization Inhibitor 4, supplied by TargetMol, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vbit+4/VBIT-4/pmc13434402-576-15-23
    Average 95 stars, based on 1 article reviews
    voltage dependent anion channel 1 oligomerization inhibitor 4 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    94
    MedChemExpress vbit4
    ( A ) Vacuole-containing VEXAS THP1 cells contain less mitochondria, as demonstrated by brightfield (BF) and single-plane confocal anti-TOM20 immunofluorescence images of UBA1 WT and UBA1 M41V THP1 monocytes treated with doxycycline for 10 d. Representative images of 2 biological replicates are shown. For more examples, see Fig. S16. Scale bar = 10 μm. ( B ) UBA1 M41V THP1 monocytes exhibit mitochondrial morphology abnormalities, indicative of impaired function. UBA1 WT and UBA1 M41V THP1 cells were treated with dox for 10 d and analyzed by transmission electron microscopy. Scale bar = 1 μm. Red arrowheads point to dilated cristae often seen in UBA1 M41V mitochondria (see also Movie S2) ( C ) UBA1 M41V THP1 monocytes exhibit a higher percentage of mitochondria with dilated cristae per cell as compared to UBA1 WT control cells. Graphs depict quantifications of mitochondrial morphology on TEM images of the experiment shown in panel b. n > 20 cells, error bar = s.e.m, * = p < 0.05, ** = p < 0.01, student’s t-test. ( D ) VEXAS THP1 cells exhibit elevated levels of cytoplasmic mitochondrial DNA, as revealed by qPCR analysis of whole cell or cytoplasmic fractions of UBA1 WT and UBA1 M41V THP1 monocytes. n = 3 biological replicates with 2 technical replicates for two different mitochondrial DNA probes (see methods), error bar = s.e.m, ** = p < 0.01, student’s t-test. ( E ) Schematic representation of experimental design to test whether mtDNA release into the cytosol activates cGAS-STING-based VEXAS inflammation. ( F ) Blocking mtDNA release into the cytosol using either a scavenger of reactive oxygen species (MitoTEMPO), an inhibitor of VDAC oligomerization <t>(VBIT4),</t> or an inhibitor of the mitochondrial permeability transition pore (CsA) dampens STING signaling and attenuates VEXAS inflammation in THP1 UBA1 M41V model cells. UBA1 WT and UBA1 M41V THP1 monocytes were treated with indicated inhibitors (10 μM MitoTEMPO, 10 μM VDAC, and 1 μM CsA) for 24h and subjected to immunoblot analysis using indicated antibodies. Graphs depict quantifications of p-STING/STING, p-STAT1/STAT1, or p-STAT3/STAT3 ratio normalized to DMSO-treated UBA1 WT THP1 monocytes. n = 3 biological replicates, error bar = s.e.m, * = p < 0.05, ** = p < 0.01, student’s t-test. ( G ) Blocking mtDNA release into the cytosol restores STING localization by preventing its trafficking to the Golgi, as evidenced by anti-STING and anti-GM130 immunofluorescence analysis of THP1 model monocytes treated as described in panel F. ( H ) Quantification of the percentage of Golgi-localized STING of the experiment depicted in panel g. n ≥ 150 cells across 10 fields, error bar = s.e.m, **** = p < 0.0001, one-way ANOVA. ( I ) Verification that treatment of THP1 VEXAS model cells with indicated inhibitors blocks mtDNA release into the cytosol, as revealed by qPCR analysis of cytoplasmic fractions of UBA1 WT and UBA1 M41V THP1 monocytes. n = 3 biological replicates, 2 technical replicates for two different mitochondrial DNA probes (see methods), error bar = s.e.m, **** = p < 0.0001, one-way ANOVA. (J) Scheme depicting the molecular mechanisms triggering STING activation in VEXAS myeloid cells. Mitochondria in VEXAS myeloid cells are defective and release mtDNA into the cytosol, causing activation of cGAS-STING signaling, which drives multi-cytokine inflammation.
    Vbit4, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vbit+4/VBIT-4/bio_rxiv__64898__2026__05__26__727520-131-34-37
    Average 94 stars, based on 1 article reviews
    vbit4 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    95
    TargetMol vbit 4 t13287
    ( A ) Vacuole-containing VEXAS THP1 cells contain less mitochondria, as demonstrated by brightfield (BF) and single-plane confocal anti-TOM20 immunofluorescence images of UBA1 WT and UBA1 M41V THP1 monocytes treated with doxycycline for 10 d. Representative images of 2 biological replicates are shown. For more examples, see Fig. S16. Scale bar = 10 μm. ( B ) UBA1 M41V THP1 monocytes exhibit mitochondrial morphology abnormalities, indicative of impaired function. UBA1 WT and UBA1 M41V THP1 cells were treated with dox for 10 d and analyzed by transmission electron microscopy. Scale bar = 1 μm. Red arrowheads point to dilated cristae often seen in UBA1 M41V mitochondria (see also Movie S2) ( C ) UBA1 M41V THP1 monocytes exhibit a higher percentage of mitochondria with dilated cristae per cell as compared to UBA1 WT control cells. Graphs depict quantifications of mitochondrial morphology on TEM images of the experiment shown in panel b. n > 20 cells, error bar = s.e.m, * = p < 0.05, ** = p < 0.01, student’s t-test. ( D ) VEXAS THP1 cells exhibit elevated levels of cytoplasmic mitochondrial DNA, as revealed by qPCR analysis of whole cell or cytoplasmic fractions of UBA1 WT and UBA1 M41V THP1 monocytes. n = 3 biological replicates with 2 technical replicates for two different mitochondrial DNA probes (see methods), error bar = s.e.m, ** = p < 0.01, student’s t-test. ( E ) Schematic representation of experimental design to test whether mtDNA release into the cytosol activates cGAS-STING-based VEXAS inflammation. ( F ) Blocking mtDNA release into the cytosol using either a scavenger of reactive oxygen species (MitoTEMPO), an inhibitor of VDAC oligomerization <t>(VBIT4),</t> or an inhibitor of the mitochondrial permeability transition pore (CsA) dampens STING signaling and attenuates VEXAS inflammation in THP1 UBA1 M41V model cells. UBA1 WT and UBA1 M41V THP1 monocytes were treated with indicated inhibitors (10 μM MitoTEMPO, 10 μM VDAC, and 1 μM CsA) for 24h and subjected to immunoblot analysis using indicated antibodies. Graphs depict quantifications of p-STING/STING, p-STAT1/STAT1, or p-STAT3/STAT3 ratio normalized to DMSO-treated UBA1 WT THP1 monocytes. n = 3 biological replicates, error bar = s.e.m, * = p < 0.05, ** = p < 0.01, student’s t-test. ( G ) Blocking mtDNA release into the cytosol restores STING localization by preventing its trafficking to the Golgi, as evidenced by anti-STING and anti-GM130 immunofluorescence analysis of THP1 model monocytes treated as described in panel F. ( H ) Quantification of the percentage of Golgi-localized STING of the experiment depicted in panel g. n ≥ 150 cells across 10 fields, error bar = s.e.m, **** = p < 0.0001, one-way ANOVA. ( I ) Verification that treatment of THP1 VEXAS model cells with indicated inhibitors blocks mtDNA release into the cytosol, as revealed by qPCR analysis of cytoplasmic fractions of UBA1 WT and UBA1 M41V THP1 monocytes. n = 3 biological replicates, 2 technical replicates for two different mitochondrial DNA probes (see methods), error bar = s.e.m, **** = p < 0.0001, one-way ANOVA. (J) Scheme depicting the molecular mechanisms triggering STING activation in VEXAS myeloid cells. Mitochondria in VEXAS myeloid cells are defective and release mtDNA into the cytosol, causing activation of cGAS-STING signaling, which drives multi-cytokine inflammation.
    Vbit 4 T13287, supplied by TargetMol, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vbit+4/VBIT-4/pm42176907-80-43-48
    Average 95 stars, based on 1 article reviews
    vbit 4 t13287 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    86
    Heumann Pharma aβ such as the vbit 4 peptide
    ( A ) Vacuole-containing VEXAS THP1 cells contain less mitochondria, as demonstrated by brightfield (BF) and single-plane confocal anti-TOM20 immunofluorescence images of UBA1 WT and UBA1 M41V THP1 monocytes treated with doxycycline for 10 d. Representative images of 2 biological replicates are shown. For more examples, see Fig. S16. Scale bar = 10 μm. ( B ) UBA1 M41V THP1 monocytes exhibit mitochondrial morphology abnormalities, indicative of impaired function. UBA1 WT and UBA1 M41V THP1 cells were treated with dox for 10 d and analyzed by transmission electron microscopy. Scale bar = 1 μm. Red arrowheads point to dilated cristae often seen in UBA1 M41V mitochondria (see also Movie S2) ( C ) UBA1 M41V THP1 monocytes exhibit a higher percentage of mitochondria with dilated cristae per cell as compared to UBA1 WT control cells. Graphs depict quantifications of mitochondrial morphology on TEM images of the experiment shown in panel b. n > 20 cells, error bar = s.e.m, * = p < 0.05, ** = p < 0.01, student’s t-test. ( D ) VEXAS THP1 cells exhibit elevated levels of cytoplasmic mitochondrial DNA, as revealed by qPCR analysis of whole cell or cytoplasmic fractions of UBA1 WT and UBA1 M41V THP1 monocytes. n = 3 biological replicates with 2 technical replicates for two different mitochondrial DNA probes (see methods), error bar = s.e.m, ** = p < 0.01, student’s t-test. ( E ) Schematic representation of experimental design to test whether mtDNA release into the cytosol activates cGAS-STING-based VEXAS inflammation. ( F ) Blocking mtDNA release into the cytosol using either a scavenger of reactive oxygen species (MitoTEMPO), an inhibitor of VDAC oligomerization <t>(VBIT4),</t> or an inhibitor of the mitochondrial permeability transition pore (CsA) dampens STING signaling and attenuates VEXAS inflammation in THP1 UBA1 M41V model cells. UBA1 WT and UBA1 M41V THP1 monocytes were treated with indicated inhibitors (10 μM MitoTEMPO, 10 μM VDAC, and 1 μM CsA) for 24h and subjected to immunoblot analysis using indicated antibodies. Graphs depict quantifications of p-STING/STING, p-STAT1/STAT1, or p-STAT3/STAT3 ratio normalized to DMSO-treated UBA1 WT THP1 monocytes. n = 3 biological replicates, error bar = s.e.m, * = p < 0.05, ** = p < 0.01, student’s t-test. ( G ) Blocking mtDNA release into the cytosol restores STING localization by preventing its trafficking to the Golgi, as evidenced by anti-STING and anti-GM130 immunofluorescence analysis of THP1 model monocytes treated as described in panel F. ( H ) Quantification of the percentage of Golgi-localized STING of the experiment depicted in panel g. n ≥ 150 cells across 10 fields, error bar = s.e.m, **** = p < 0.0001, one-way ANOVA. ( I ) Verification that treatment of THP1 VEXAS model cells with indicated inhibitors blocks mtDNA release into the cytosol, as revealed by qPCR analysis of cytoplasmic fractions of UBA1 WT and UBA1 M41V THP1 monocytes. n = 3 biological replicates, 2 technical replicates for two different mitochondrial DNA probes (see methods), error bar = s.e.m, **** = p < 0.0001, one-way ANOVA. (J) Scheme depicting the molecular mechanisms triggering STING activation in VEXAS myeloid cells. Mitochondria in VEXAS myeloid cells are defective and release mtDNA into the cytosol, causing activation of cGAS-STING signaling, which drives multi-cytokine inflammation.
    Aβ Such As The Vbit 4 Peptide, supplied by Heumann Pharma, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vbit+4/4+as+a%CE%B2+peptide+such+the+vbit/pm42106151-385-11-36
    Average 86 stars, based on 1 article reviews
    aβ such as the vbit 4 peptide - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    Image Search Results


    ( A ) Vacuole-containing VEXAS THP1 cells contain less mitochondria, as demonstrated by brightfield (BF) and single-plane confocal anti-TOM20 immunofluorescence images of UBA1 WT and UBA1 M41V THP1 monocytes treated with doxycycline for 10 d. Representative images of 2 biological replicates are shown. For more examples, see Fig. S16. Scale bar = 10 μm. ( B ) UBA1 M41V THP1 monocytes exhibit mitochondrial morphology abnormalities, indicative of impaired function. UBA1 WT and UBA1 M41V THP1 cells were treated with dox for 10 d and analyzed by transmission electron microscopy. Scale bar = 1 μm. Red arrowheads point to dilated cristae often seen in UBA1 M41V mitochondria (see also Movie S2) ( C ) UBA1 M41V THP1 monocytes exhibit a higher percentage of mitochondria with dilated cristae per cell as compared to UBA1 WT control cells. Graphs depict quantifications of mitochondrial morphology on TEM images of the experiment shown in panel b. n > 20 cells, error bar = s.e.m, * = p < 0.05, ** = p < 0.01, student’s t-test. ( D ) VEXAS THP1 cells exhibit elevated levels of cytoplasmic mitochondrial DNA, as revealed by qPCR analysis of whole cell or cytoplasmic fractions of UBA1 WT and UBA1 M41V THP1 monocytes. n = 3 biological replicates with 2 technical replicates for two different mitochondrial DNA probes (see methods), error bar = s.e.m, ** = p < 0.01, student’s t-test. ( E ) Schematic representation of experimental design to test whether mtDNA release into the cytosol activates cGAS-STING-based VEXAS inflammation. ( F ) Blocking mtDNA release into the cytosol using either a scavenger of reactive oxygen species (MitoTEMPO), an inhibitor of VDAC oligomerization (VBIT4), or an inhibitor of the mitochondrial permeability transition pore (CsA) dampens STING signaling and attenuates VEXAS inflammation in THP1 UBA1 M41V model cells. UBA1 WT and UBA1 M41V THP1 monocytes were treated with indicated inhibitors (10 μM MitoTEMPO, 10 μM VDAC, and 1 μM CsA) for 24h and subjected to immunoblot analysis using indicated antibodies. Graphs depict quantifications of p-STING/STING, p-STAT1/STAT1, or p-STAT3/STAT3 ratio normalized to DMSO-treated UBA1 WT THP1 monocytes. n = 3 biological replicates, error bar = s.e.m, * = p < 0.05, ** = p < 0.01, student’s t-test. ( G ) Blocking mtDNA release into the cytosol restores STING localization by preventing its trafficking to the Golgi, as evidenced by anti-STING and anti-GM130 immunofluorescence analysis of THP1 model monocytes treated as described in panel F. ( H ) Quantification of the percentage of Golgi-localized STING of the experiment depicted in panel g. n ≥ 150 cells across 10 fields, error bar = s.e.m, **** = p < 0.0001, one-way ANOVA. ( I ) Verification that treatment of THP1 VEXAS model cells with indicated inhibitors blocks mtDNA release into the cytosol, as revealed by qPCR analysis of cytoplasmic fractions of UBA1 WT and UBA1 M41V THP1 monocytes. n = 3 biological replicates, 2 technical replicates for two different mitochondrial DNA probes (see methods), error bar = s.e.m, **** = p < 0.0001, one-way ANOVA. (J) Scheme depicting the molecular mechanisms triggering STING activation in VEXAS myeloid cells. Mitochondria in VEXAS myeloid cells are defective and release mtDNA into the cytosol, causing activation of cGAS-STING signaling, which drives multi-cytokine inflammation.

    Journal: bioRxiv

    Article Title: Cell autonomous inflammation in VEXAS is mediated by cGAS-STING

    doi: 10.64898/2026.05.26.727520

    Figure Lengend Snippet: ( A ) Vacuole-containing VEXAS THP1 cells contain less mitochondria, as demonstrated by brightfield (BF) and single-plane confocal anti-TOM20 immunofluorescence images of UBA1 WT and UBA1 M41V THP1 monocytes treated with doxycycline for 10 d. Representative images of 2 biological replicates are shown. For more examples, see Fig. S16. Scale bar = 10 μm. ( B ) UBA1 M41V THP1 monocytes exhibit mitochondrial morphology abnormalities, indicative of impaired function. UBA1 WT and UBA1 M41V THP1 cells were treated with dox for 10 d and analyzed by transmission electron microscopy. Scale bar = 1 μm. Red arrowheads point to dilated cristae often seen in UBA1 M41V mitochondria (see also Movie S2) ( C ) UBA1 M41V THP1 monocytes exhibit a higher percentage of mitochondria with dilated cristae per cell as compared to UBA1 WT control cells. Graphs depict quantifications of mitochondrial morphology on TEM images of the experiment shown in panel b. n > 20 cells, error bar = s.e.m, * = p < 0.05, ** = p < 0.01, student’s t-test. ( D ) VEXAS THP1 cells exhibit elevated levels of cytoplasmic mitochondrial DNA, as revealed by qPCR analysis of whole cell or cytoplasmic fractions of UBA1 WT and UBA1 M41V THP1 monocytes. n = 3 biological replicates with 2 technical replicates for two different mitochondrial DNA probes (see methods), error bar = s.e.m, ** = p < 0.01, student’s t-test. ( E ) Schematic representation of experimental design to test whether mtDNA release into the cytosol activates cGAS-STING-based VEXAS inflammation. ( F ) Blocking mtDNA release into the cytosol using either a scavenger of reactive oxygen species (MitoTEMPO), an inhibitor of VDAC oligomerization (VBIT4), or an inhibitor of the mitochondrial permeability transition pore (CsA) dampens STING signaling and attenuates VEXAS inflammation in THP1 UBA1 M41V model cells. UBA1 WT and UBA1 M41V THP1 monocytes were treated with indicated inhibitors (10 μM MitoTEMPO, 10 μM VDAC, and 1 μM CsA) for 24h and subjected to immunoblot analysis using indicated antibodies. Graphs depict quantifications of p-STING/STING, p-STAT1/STAT1, or p-STAT3/STAT3 ratio normalized to DMSO-treated UBA1 WT THP1 monocytes. n = 3 biological replicates, error bar = s.e.m, * = p < 0.05, ** = p < 0.01, student’s t-test. ( G ) Blocking mtDNA release into the cytosol restores STING localization by preventing its trafficking to the Golgi, as evidenced by anti-STING and anti-GM130 immunofluorescence analysis of THP1 model monocytes treated as described in panel F. ( H ) Quantification of the percentage of Golgi-localized STING of the experiment depicted in panel g. n ≥ 150 cells across 10 fields, error bar = s.e.m, **** = p < 0.0001, one-way ANOVA. ( I ) Verification that treatment of THP1 VEXAS model cells with indicated inhibitors blocks mtDNA release into the cytosol, as revealed by qPCR analysis of cytoplasmic fractions of UBA1 WT and UBA1 M41V THP1 monocytes. n = 3 biological replicates, 2 technical replicates for two different mitochondrial DNA probes (see methods), error bar = s.e.m, **** = p < 0.0001, one-way ANOVA. (J) Scheme depicting the molecular mechanisms triggering STING activation in VEXAS myeloid cells. Mitochondria in VEXAS myeloid cells are defective and release mtDNA into the cytosol, causing activation of cGAS-STING signaling, which drives multi-cytokine inflammation.

    Article Snippet: Cells were treated for specified time periods with the following: H-151 (1 μM or 10 μM; MedChemExpress, HY-112693), SN-011 (10 μM; MedChemExpress HY-145010), MitoTEMPO (10 μM; MedChemExpress, HY-112879), Cyclosporin A (1 μM; MedChemExpress HY-B0579), VBIT4 (10 μM; MedChemExpress, HY-129122), 4μ8c (100 μM; MedChemExpress, HY-19707), GSK2606414 (5 μM; MedChemExpress, HY-18072), Ceapin-A7 (6 μM; MedChemExpress, HY-108434), PKR-IN-C16 (0.6 μM; MedChemExpress, HY-13977A), GCN2-IN-1 (1 μM; MedChemExpress, HY-100877), CP26 (1 μM, 1.25 μM, 2 μM, and 5 μM; MedChemExpress, HY-49116), Eeyarestatin I (10 μM; MedChemExpress, HY-110078), TAK-243 (5 nM; MedChemExpress, HY-100487), cyclohexamide (50 μg/mL; Sigma Aldrich, C4859), BafA1 (1 μM or 10 μM; MedChemExpress, HY-100558), and NSC697923 (3 μM or 4 μM; MedChem Express, HY-13811).

    Techniques: Immunofluorescence, Transmission Assay, Electron Microscopy, Control, Blocking Assay, Permeability, Western Blot, Activation Assay